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Fibrinogen, a 340 KDa plasma glycoprotein, is essential for fibrin clot formation and platelet
aggregation. Fibrinogen is composed of three pairs of polypeptide chains called Aα, Bβ and
γ. The N-termini of all six chains are associated in the central E domain, while the peripheral
D domains are composed predominantly of the C-terminal regions of Bβ and γ. The C-termini
of the Aα chains, known as αC-domains, fold back from D and interact with each other and
with the central E domain (1). Familial dysfibrinogenemia, caused by qualitative changes in
circulating fibrinogen, shows a high phenotypic heterogeneity; nearly half the cases are
clinically silent, a quarter show a bleeding tendency, and the remaining experience thrombosis
with or without haemorrhage (2). A prolonged thrombin time that is corrected by the addition
of normal plasma and discrepancy between functional and antigenic levels of circulating
fibrinogen are usually diagnostic.
We report a new case of hypodysfibrinogenemia in a Caucasian woman with a life-long mild
bleeding disorder characterised by menorrhagia and postpartum bleeding. At age 60 she
developed cholecystitis. Laboratory studies showed prolonged thromboplastin, prothrombin,
thrombin and reptilase times that were corrected in mixing studies. Assays of factors II, V, VII,
X, and XIII were normal. Clottable fibrinogen was 59 mg/dl and fibrinogen antigen 184 mg/
dl (reference values: 200–400 mg/dl). The cholecystitis resolved with medical therapy, and she
was diagnosed with congenital dysfibrinogenemia. Three years later she suffered a crushing
injury to her left fingers; after 1–2 weeks, the initial bruising became cyanotic and the third
finger gangrenous. She was treated with cryoprecipitate infusions, raising clottable fibrinogen
levels from <60 to 218 mg/dl. A magnetic resonance examination the next day revealed
occlusion of the left carotid from its origin at the aorta, and high-grade stenosis of the right
brachiocephalic artery. She did not receive additional cryoprecipitate and the left third finger
was amputated without complications. A computerised tomographic angiogram performed one
month later confirmed occlusion of the left subclavian artery with vertebral artery “steal
syndrome”. A large plaque at the origin of the right subclavian artery and aortic atheromas
were also noted.
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Fibrin polymerisation studies with the patient’s plasma showed a near absent response in
turbidity (Fig. 1A). The patient’s daughter and granddaughter, clinically asymptomatic, had
clottable fibrinogen levels of 131 and 177 mg/dl (3), respectively. Their plasmas showed a
severe polymerisation defect with a prolonged lag phase and markedly diminished final
turbidity (Fig. 1A). Immunoblot analysis with a polyclonal antibody (Dako, Carpenteria, CA,
USA) showed no normal Aα chain in the patient (data not shown). Subsequent studies with
Aα chain-specific antibodies (Y18, Gaubius Institute, TNO, Leiden, The Netherlands) showed
a unique truncated circulating Aα chain of ~56 KDa in the patient (Fig. 1B). This truncated
chain was not detected with antibodies against the αC residues 603–610 (F48, kindly provided
by Gary Matsueda, Bristol-Meyers Squibb, New Brunswick, NJ, USA). The densitometry
showed that patient’s relatives expressed approximately equal levels of both normal and
truncated circulating Aα chains.
We isolated DNA from the patient and performed genomic DNA sequence analysis of PCR-
amplified products corresponding to the exonic, intronic flanking regions and promoter of the
FGA gene. We identified the IVS4+1G>T mutation in heterozygosity. This transversion is the
most prevalent mutation causing afibrinogenemia in homozygous individuals (4). The
consensus splice donor site in intron 4 is lost, leading to alternative splicing and degradation
of the transcript (5). This mutation has been linked to different haplotypes suggesting that it is
a mutational hot spot in the FGA gene (4).
In the other allele, we found the 4841delC mutation, reported in the AαPerth variant (6). This
deletion induces a frameshift in the αC domain causing truncation of the Aα chain at residue
517 including incorporation of 23 new residues. Therefore, the circulating protein lacks the
terminal RGDS sites, the Lys508 residue that participates in FXIII-mediated crosslinking, and
a tPA binding domain (1). Analysis of cloned PCR products showed the AαPerth 4841delC was
linked to the Ala312 polymorphism. This polymorphism increases FXIII-mediated
crosslinking activity and resistance to fibrinolysis (7). It has been reported that carriers are
more likely to suffer venous thromboembolism (8).
At least 25 other familial mutations have been reported in the αC domain
(http://www.geht.org/) and many of these are associated with reduced expression of the mutant
chain. No circulating AαOtago chain was found in heterozygotes for Otago truncation (9), 0.2:1
ratio in AαLincoln (10), Willmington (11) and the Perth case (6), and less than 10% of the
circulating Aα chains in fibrinogen Marburg (12), suggesting the αC domain is involved in
fibrinogen assembly and/or secretion from the hepatocyte (6,13). However, the hemizygous
patient, expressing only the variant chain, and her heterozygous relatives, showed near normal
circulating levels of truncated Aα chains, indicating the absence of a severe defect in mature
protein folding in this case.
Interestingly, in contrast to heterozygous carriers in the first reported familial case, our patient’s
relatives had no obvious bleeding tendency. Thus, our patient’s bleeding phenotype apparently
reflects her compound mutation, hypofibrinogenemia resulting mainly from the IVS4+1G>T
and the polimerisation defect due to the αC domain truncation. The etiology of the thrombotic
complications associated with her hand injury is likely complex. Her atheromatous disease is
likely causal, but the cryoprecipitate infusions and her fibrinogen genotype, both the AαPerth
and the 312Ala polymorphism, probably exacerbated development of the large vessel
occlusions.
In summary, our data show dysfibrinogenemia associated with the Perth mutation has a
heterogeneous phenotype and suggest factors other than the mutation impact on plasma
fibrinogen levels.
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Figure 1. Fibrin polimerisation and Aα chain characterisation
A) Representative fibrin polymerisation curves. Thrombin (0.1 U/ml) was added to plasma
1:10 diluted in HBS (CaCl2 10mM) and the polymerisation was monitored in triplicate, in a
microplate reader at room temperature. Turbidity increase was abolished in the patient’s
plasma, while the daughter and granddaughter’s revealed a longer lag-phase and a severe
reduction in final turbidity. Control plasma was from a healthy non-related donor. B)
Immunoblot analysis of reduced plasma samples run on 7.5% SDS-PAGE, developed with an
Aα chain specific antibody. While no normal Aα chain could be seen in the patient, the daughter
and granddaughter showed both normal and variant Aα chains at similar levels. Loading was
normalised to total plasma protein, and verified by Ponceau stain after SDS-PAGE (data not
shown).
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